Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouA private label facial serum is rarely a “finished” formula. Actives get discontinued, a supplier changes its carrier grade, a fragrance house issues a new base version, and suddenly the factory needs a decision…
A private label facial serum is rarely a “finished” formula. Actives get discontinued, a supplier changes its carrier grade, a fragrance house issues a new base version, and suddenly the factory needs a decision before the next GCC production run. The question buyers ask most often is deceptively simple: who is actually allowed to approve that substitution? This guide answers it operationally — with a sign-off matrix, an evidence pack you can forward to your manufacturer today, a realistic timeline, and the failure modes that cause shipments to be held at the port or pulled from a launch calendar.
Informational only, not legal advice. Market classification and filing obligations must be confirmed with your in-market regulatory agent for each GCC state you sell into.
An INCI name identifies a substance family, not a commercial material. Two lots with the same INCI can differ in active assay, salt form, solvent or carrier, particle size, degree of polymerization, impurity profile, color, odor, and preservative system. In a serum — where water content, pH, and electrolyte balance are already tight — those differences show up as viscosity drift, phase separation, haze in clear gel, or a change in how the product spreads and absorbs.
The minimum acceptable evaluation sequence for a same-INCI substitution is:
| Change type | Who must authorize | Hard evidence required before bulk production |
|---|---|---|
| New supplier, same INCI, same grade and site-verified equivalence | Brand owner (formula owner) + manufacturer QA; regulatory informed in writing | Side-by-side spec and COA, lab trial result, stability checkpoints |
| Different grade, purity, carrier, or manufacturing site | Brand owner + safety assessor + regulatory | Full equivalence dossier, accelerated stability, updated safety file statement |
| Active concentration change | Brand owner + safety assessor + regulatory | New formula version, stability, efficacy or claim support review |
| Preservative system change | Safety assessor (lead) + brand owner | Preservative efficacy test in final pack, pH and micro data |
| Fragrance base version or fragrance supplier change | Brand owner + safety assessor + regulatory | IFRA certificate matched to actual use (rinse-off vs. leave-on), allergen declaration, exposure re-assessment |
| Colorant change | Regulatory first, then brand owner | Market-by-market permitted colorant confirmation; not treated as an ordinary ingredient |
| Bottle, dropper, pump, gasket, dip tube, or coating change | Brand owner + packaging supplier + QA | In-pack compatibility and fill test, component drawings and material specs |
| Label text, INCI order, or claim wording change | Brand marketing + regulatory claim review | Claim matrix with evidence ID and artwork release record |
START HERE
1. Is it the same INCI, same grade, same supplier site, documented in writing?
YES -> Administrative re-qualification: COA compare + lab trial + stability checkpoints.
Sign-off: manufacturer QA + brand operations. Regulatory notified, not asked.
NO -> Continue.
2. Does the change touch fragrance, preservative, colorant, ethanol/denatured solvent,
or the antioxidant system?
YES -> Full safety re-review. Safety assessor leads. Do not schedule bulk.
NO -> Continue.
3. Does it change any label statement, INCI order, allergen declaration, or claim?
YES -> Stop. Label and claim review before any production date is confirmed.
NO -> Continue.
4. Does it change viscosity, pH, color, odor, fill weight, or pump/dropper performance?
YES -> In-pack compatibility and fill test on the production component.
5. Is the SKU already notified or registered in a GCC market?
YES -> Ask the in-market agent, in writing, whether an update or re-notification is needed.
BOUNDARY CASES -> drug-boundary claims, nano materials, color additives, or a new active
not previously assessed: use specialist counsel, extra testing, or an alternative pathway.
| Phase | Buyer action | Manufacturer action | Evidence output | Fastest safe | Standard |
|---|---|---|---|---|---|
| 0. Change request and classification | Submit written change request with target markets and SKU list | Issue change control form and equivalence screen | Signed change request, classification note | 2–3 days | 3–5 days |
| 1. Equivalence screen and lab trial | Approve trial brief and use level | COA comparison, lab batch, sensory panel | Comparison table, trial batch record, sensory notes | 5–10 days | 2 weeks |
| 2. Safety and regulatory review | Obtain in-market agent statement per GCC state | Update safety assessment inputs, allergen calculation | Safety file statement, regulatory assessment | 5–10 days (parallel) | 2–3 weeks |
| 3. Stability and in-pack compatibility | Lock packaging specification and component drawings | Accelerated stability and fill test in production pack | Stability report, compatibility report | 4 weeks accelerated (real-time continues) | 8–12 weeks |
| 4. Claim and label lock | Approve claim matrix and artwork | Verify INCI order and allergen text against BOM | Approved artwork release record | 3–5 days | 1–2 weeks |
| 5. Pilot run | Approve pilot samples against golden reference | Run pilot batch, retain samples | Pilot batch record, retention samples | 1 week | 2 weeks |
| 6. Documentation handoff | Confirm dossier completeness with agent | Compile COA, SDS, stability, compatibility, batch records | Complete documentation pack | 3–5 days | 1 week |
What may be compressed: paperwork sequencing, parallel lab and regulatory review, and the number of pilot iterations — provided the golden reference sample is unambiguous. What may not: safety review, allergen calculation, in-pack compatibility, and preservative efficacy where relevant.
Subject: Ingredient substitution request - facial serum - approval required before bulk
Share the controlled formula version number and the SKU list affected.
Describe the change: old material vs new material, supplier, grade, and site.
Attach side-by-side specification and COA for both materials.
Attach SDS for the new material.
State whether fragrance, preservative, colorant, solvent, or antioxidant system is affected.
Provide the IFRA certificate and allergen declaration if fragrance is affected.
Confirm the IFRA category matches a leave-on facial serum, not a rinse-off product.
Provide the proposed use level and confirm it matches the approved formula.
Run a lab trial and share viscosity, pH, appearance, and odor results.
Provide the accelerated stability protocol and checkpoint schedule.
Provide the in-pack compatibility protocol using the production bottle and dropper.
Confirm whether a preservative efficacy test is required, and why or why not.
List every label element that changes: INCI order, allergen text, warnings, claims.
Provide the finished-product evidence for each performance claim retained.
Confirm whether any GCC market notification or dossier needs updating.
Provide a written regulatory assessment per destination market.
Submit the signed change control record with named approvers.
Confirm the pilot batch date only after brand approval is logged.
Provide retention sample quantities and storage conditions.
Attach the goods-in documentation gate rule for the new material.
Confirm the golden reference sample for sensory comparison.
State the earliest bulk date after all approvals are complete.
| Lever / Decision | Primary impact | What to do (specific) | Do NOT cut (red line) | Evidence needed (request) | Expected timeline effect |
|---|---|---|---|---|---|
| Accept a same-INCI supplier swap | Cost and supply continuity | Run COA comparison plus lab trial at approved use level before scheduling bulk | Specification and COA comparison with assay and impurity limits | Side-by-side spec and COA, trial batch record | Adds 1–2 weeks; avoids 4+ week rework |
| Change fragrance base version | Safety file, allergen label, sensory identity | Re-issue allergen calculation and confirm IFRA category for leave-on use | IFRA certificate matched to actual use plus allergen declaration | IFRA certificate, allergen statement, exposure note | Adds 1–2 weeks to label lock |
| Change preservative system | Microbial safety | Commission a preservative efficacy test in the production pack | Challenge test pass criteria in final packaging | Preservative efficacy test report | Adds 3–4 weeks; non-negotiable |
| Change dropper or bottle component | Leak risk, dose consistency, label adhesion | Fill test in production components with inverted storage | In-pack compatibility test with gasket and coating specs | Compatibility report, component drawings | Adds 4 weeks accelerated |
| Compress stability testing | Launch speed | Use accelerated conditions with real-time running in parallel, not instead | Minimum accelerated checkpoints at defined intervals | Stability protocol and checkpoint data | Saves 4–6 weeks only if real-time continues post-launch |
| Retain performance claims | Marketing copy and marketplace compliance | Map each claim to a finished-product evidence ID before artwork approval | Finished-product substantiation at marketed use level | Claim matrix with evidence IDs, study report | Prevents late-stage copy pull; may add 2 weeks |
| Defer GCC regulatory check | Market release | Get written market-by-market assessment before the pilot batch | Per-market regulatory statement on dossier and label updates | Signed regulatory assessment | Avoids 2–6 week hold at shipment |
| Allow factory-side substitution at bulk | Formula integrity and audit standing | Require signed change control before any material enters the tank | Brand signature on change control record | Signed change control, lot-linked COA | Prevents full-batch rejection |
| Pilot run before documentation lock | Cost of rework | Sequence pilot after label lock and safety review, not before | Approved artwork release and safety statement | Artwork release record, safety file statement | Saves one full pilot iteration |
No. The factory can propose a substitution, but identical INCI does not mean identical material. Assay, grade, carrier, impurities, and site can all shift performance and safety. A written equivalence screen, lab trial, and stability checkpoints are the minimum before approval — and the brand owner must sign.
Both, in different lanes. The brand owner authorizes anything that changes the formula, label, claim, or consumer experience. The safety assessor owns the safety conclusion. The in-market regulatory responsible entity owns the filing position. Manufacturer QA owns batch-level traceability. No single party can authorize a change alone.
It depends on the material changed, the market, and how the product is classified there. This must be answered in writing by your in-market agent for each destination — not assumed. Build that written statement into the approval gate before bulk is scheduled.
No. Supplier changes are a standard revalidation trigger. At minimum, run COA comparison, a lab trial, stability checkpoints, and in-pack compatibility. If the change touches preservative, pH, or packaging, add a preservative efficacy test.
Roughly 4–6 weeks on the fastest safe path where the change is administrative and documentation is clean, and 8–12 weeks on the standard path when stability, in-pack compatibility, and regulatory updates are in scope. Most delays come from documentation gaps, not from the lab.
If you are planning a facial serum substitution for a GCC launch, send us the change description, the target markets, the SKU and format list, your positioning, the packaging direction, and your timeline target. That combination is what allows a formulation and compliance team to return a scope, an evidence list, and a realistic production window instead of a generic price sheet.